The research team, led by Saikat Mandal and Guruprasad Aithal of the Nottingham Digestive Diseases Centre at the University of Nottingham, together with colleagues at Hull, Sheffield, Belfast and Imperial College London, mined the US Food and Drug Administration’s Adverse Event Reporting System, known as FAERS, covering the period from the third quarter of 2016 through the first quarter of 2026. Out of 4,700,843 total reports, 19,820 identified a CAR T-cell product as the primary suspect drug, and 734 of those contained at least one hepatic adverse event. To capture liver injury comprehensively, the investigators built a prespecified dictionary of 244 MedDRA-coded terms spanning everything from mild transaminase elevations to frank hepatic failure.

The timing of the reported liver events proved strikingly consistent. The median onset was just five days after infusion, and 73.5 percent of all hepatic reports occurred within the first two weeks. That early window is precisely when cytokine release syndrome, the systemic inflammatory cascade triggered by activated T cells, reaches its peak intensity. When the researchers examined the text of the hepatic reports, they found that CRS was co-mentioned in 77.0 percent of them, whereas terms from the haemophagocytic lymphohistiocytosis spectrum, including the related immune effector cell-associated haemophagocytic syndrome, appeared in only 9.5 percent. This imbalance immediately suggested that the inflammatory storm, rather than a rarer hyperinflammatory syndrome, might be the dominant driver of liver-related signals.

To test that hypothesis formally, the team deployed a battery of classic pharmacovigilance statistics: the reporting odds ratio, the proportional reporting ratio, the information component from a Bayesian confidence propagation neural network, and the empirical Bayes geometric mean. Each metric compares how often a given event is reported with a suspect drug against how often it appears with all other drugs, and requiring agreement across multiple methods helps filter out statistical noise. In the pooled analysis, hepatic events showed a modest but detectable association with CAR T-cell products, with a reporting odds ratio of 1.36. The crucial experiment came next: when the researchers excluded every report that also mentioned cytokine release syndrome, the pooled signal collapsed to 0.54, effectively falling below the threshold expected by chance. Excluding HLH-spectrum reports, by contrast, left the association intact.

That asymmetry is the analytical heart of the study. If liver injury were an independent manifestation of CAR T-cell toxicity, stripping out CRS reports should have left the signal largely undiminished. Instead, the signal vanished, implying that the liver abnormalities captured in spontaneous reporting databases are, in the great majority of cases, a downstream feature of the cytokine storm rather than a separate immune-mediated process. This distinction matters clinically, because the two scenarios demand different responses. CRS is typically managed with the interleukin-6 receptor antibody tocilizumab and supportive care, whereas suspected immune-mediated drug-induced liver injury or HLH may require corticosteroids, etoposide, or other immunosuppressive strategies, and misattributing the cause can delay appropriate treatment.

The product-level analysis added a provocative wrinkle. Among the individual CAR T-cell constructs, idecabtagene vicleucel, the anti-BCMA therapy approved for multiple myeloma, showed the most consistent hepatic reporting pattern across all four statistical methods. More importantly, it retained a supportive signal even after the researchers excluded reports co-mentioning CRS, with a reporting odds ratio of 2.22 and a 95 percent confidence interval of 1.38 to 3.57. In other words, a residue of liver-injury reporting persisted that could not be explained away by the cytokine storm alone. No other product showed comparable persistence, and no product retained four-method positivity beyond the 14-day mark, reinforcing the overall picture of early, CRS-linked injury with one notable exception.

Phenotype analysis deepened the product-specific picture. By clustering the individual MedDRA terms within hepatic reports, the researchers identified mixed hepatocellular and cholestatic reporting patterns that differed across products, a pattern reminiscent of how classical drug-induced liver injury presents in distinct biochemical signatures. Cholestatic patterns, in which bile flow is impaired and alkaline phosphatase rises disproportionately, can point toward different mechanistic pathways than pure hepatocellular injury. The authors suggest these residual, CRS-independent patterns, particularly for idecabtagene vicleucel, warrant prospective clinical evaluation with protocolized liver biochemistry monitoring, rather than reliance on the fragmented and potentially biased data of spontaneous reporting.

Spontaneous reporting databases are powerful but imperfect instruments. FAERS aggregates millions of reports, yet it suffers from underreporting, reporting bias, duplicate submissions, and the well-known Weber effect, in which adverse events are reported more frequently in the period immediately after a drug’s approval. The researchers addressed these vulnerabilities with several safeguards: they deduplicated reports, restricted the analysis to records naming a CAR T-cell product as the primary suspect, and performed sensitivity analyses examining delayed-onset events and specific hepatic phenotypes. They also sought directional confirmation in a second database, Canada Vigilance, where the proportion of hepatic reports co-mentioning CRS was similar at 75.0 percent. However, only four hepatic adverse-event reports existed in the Canadian data, far too few for meaningful product-level comparison, underscoring how sparse real-world evidence remains for some of these newer toxicities.

The study’s framing of the differential diagnosis is one of its most useful contributions to practicing clinicians. Liver dysfunction after CAR T-cell infusion can arise from at least three distinct mechanisms: the inflammatory milieu of cytokine release syndrome, the hyperinflammatory HLH-like syndrome that shares laboratory features with familial hemophagocytic lymphohistiocytosis, and a conventional immune-mediated drug-induced liver injury resembling idiosyncratic hepatotoxicity from small-molecule drugs. Each mechanism has a different temporal signature, a different biomarker profile, and a different treatment algorithm. By quantifying how frequently each appears in real-world reporting, the Nottingham-led team has given clinicians an evidence-based prior for interpreting liver enzyme abnormalities in the days and weeks following infusion.

The authors are careful to emphasize the limits of their findings. Pharmacovigilance signals identify statistical associations, not causation, and the absence of denominator data means incidence rates cannot be calculated from FAERS or Canada Vigilance. The persistent idecabtagene vicleucel signal, while intriguing, is based on a modest number of reports and requires confirmation in prospective cohorts with systematic liver monitoring. Still, the study arrives at a moment when CAR T-cell therapy is expanding rapidly beyond academic centers and into community oncology, meaning more clinicians than ever will confront unexplained liver enzyme elevations in treated patients. For most, the message is reassuring: hepatic events are predominantly early, temporally tied to the cytokine storm, and likely to resolve as the inflammatory phase subsides. For a subset of patients, particularly those receiving BCMA-directed therapy, the possibility of a CRS-independent liver injury remains open, and the authors argue that only carefully designed prospective studies can close it. The work was supported by the NIHR Nottingham Biomedical Research Centre and UK Research and Innovation, and the underlying data are publicly accessible, allowing other groups to interrogate and extend the analysis as the CAR T-cell treated population continues to grow.

Subject of Research: Hepatic adverse-event reporting patterns following CAR T-cell therapy analyzed through pharmacovigilance databases

Article Title: Hepatic adverse-event reporting after CAR T-cell therapy: a pharmacovigilance analysis of FAERS and Canada Vigilance

Article References: Mandal, S., Maji, M., Dhali, A., & Aithal, G. (2026). Hepatic adverse-event reporting after CAR T-cell therapy: a pharmacovigilance analysis of FAERS and Canada Vigilance. Annals of Hematology. https://doi.org/10.1007/s00277-026-07318-0

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07318-0

Keywords: CAR T-cell therapy, hepatic adverse events, cytokine release syndrome, haemophagocytic lymphohistiocytosis, pharmacovigilance, FAERS, Canada Vigilance, drug-induced liver injury, idecabtagene vicleucel, immunotherapy toxicity, liver injury, hematology

To dissect the question, the researchers turned to a mouse model. HAV is a fastidious virus with a narrow host range, and the team worked with mice lacking the gene for the type I interferon receptor, Ifnar1, which renders the animals permissive to HAV replication and allows the virus to reach the liver and cause measurable disease. By challenging male and female Ifnar1-deficient mice with HAV under controlled laboratory conditions, the investigators could hold exposure, diet, environment, and age constant, isolating sex as the variable. This design directly addresses the central confound of human epidemiology, where social and behavioral factors are difficult to disentangle from physiology.

The results were striking. Male mice replicated the virus to higher levels than females and shed more of it, indicating that the virus finds a more hospitable environment in the male body. More importantly for disease, the males developed accelerated and more severe liver injury. Serum alanine aminotransferase, or ALT, a standard clinical marker of hepatocyte damage, rose to higher levels in infected males than in females. Histological examination revealed greater immune cell infiltration into the livers of male mice, and molecular profiling showed elevated intrahepatic expression of chemokines, the signaling molecules that recruit inflammatory cells to tissue, as well as higher expression of interferon-stimulated genes, the cellular programs activated during antiviral responses.

That combination of findings paints a coherent picture of immunopathology. Hepatitis A is classically understood as a disease in which the immune response to the virus, rather than the virus itself, drives much of the liver damage. The male mice in this study mounted a more exuberant inflammatory response in the liver, with more chemokine production drawing more immune cells into the tissue, and the consequence was more hepatocyte injury. The higher viral loads in males suggest that the sex difference operates on both sides of the host-pathogen relationship, influencing not only how violently the immune system reacts but also how effectively the virus replicates and spreads within the host.

Crucially, the researchers tested whether age modified these effects by comparing young and older adult mice. The sex differences persisted across both age groups, indicating that the male disadvantage in HAV pathogenesis is not a feature of a particular developmental window but a stable characteristic of sex biology. This matters for interpreting human data, because hepatitis A incidence and severity vary with age, and any sex-based analysis must account for that. The mouse findings suggest that, at least in this model, age does not erase or substantially reshape the fundamental sex difference in infection outcome.

With the male-female difference firmly established, the team moved to the mechanistic question: what is it about being female that confers protection? The leading candidate was estrogen, the dominant female sex hormone, which is known to influence immune function and liver physiology in many contexts. The researchers performed ovariectomy, surgical removal of the ovaries, on female mice to eliminate endogenous estrogen production. When these ovariectomized mice were infected with HAV, they fared markedly worse than female mice that had undergone sham surgery. They carried higher viral loads in the liver, showed greater elevations in serum ALT, and displayed more severe liver pathology on histological examination. In other words, removing the ovaries made female mice look more like males in their response to the virus.

The converse experiment sealed the argument. When ovariectomized mice were given estradiol implants to restore estrogen signaling, their viral loads and ALT activity fell again, moving back toward the protected phenotype of intact females. This hormone-replacement result demonstrates that estrogen itself, rather than some other consequence of ovarian function, exerts a protective effect against HAV pathogenesis. The finding aligns with a broader literature on sex hormones and antiviral immunity, in which estrogen has been shown to modulate inflammatory signaling, enhance certain antiviral defenses, and generally temper the kind of tissue-damaging immunopathology that characterizes severe hepatitis.

The team then probed how estrogen delivers its protection at the cellular level. The canonical estrogen receptor, ESR1, is encoded by the Esr1 gene, and hepatocytes, the working cells of the liver, express this receptor and can respond directly to estrogen through it. One plausible mechanism was that estrogen acts on hepatocytes themselves, signaling through ESR1 to make them more resistant to injury or less permissive to viral replication. To test this, the researchers generated female Ifnar1-deficient mice lacking hepatocellular expression of the estrogen receptor. If direct ESR1 signaling in hepatocytes were the key to protection, these mice should have lost their female advantage. Instead, they were phenotypically similar to mice that still expressed Esr1 in their hepatocytes, indicating that direct ESR1 signaling in hepatocytes is not essential for protection against HAV pathogenesis.

This negative result is scientifically important because it redirects the search for mechanism. If estrogen is not protecting the liver by acting directly on hepatocytes, then its protective effect likely operates through other cell types or systemic pathways. Candidates include immune cells, which are richly responsive to estrogen and which drive the immunopathology of hepatitis; non-parenchymal liver cells such as Kupffer cells and liver sinusoidal endothelial cells, which orchestrate inflammatory signaling in the organ; or broader endocrine effects on metabolism and antiviral state. The study does not identify the responsible mechanism, but by ruling out the most obvious hepatocyte-autonomous explanation, it sharpens the questions for future work.

Taken together, the findings carry implications that extend beyond hepatitis A. They establish, in a controlled experimental system, that sex influences both the magnitude of viral replication and the severity of liver disease in HAV infection, and they identify female sex hormones as the protective factor. For clinicians and epidemiologists, the work supports the interpretation that the excess of severe hepatitis A among men reflects, at least in part, intrinsic biological vulnerability rather than behavior alone. For virologists, the study adds HAV to the growing list of infections whose course is shaped by sex-dependent biology, and it provides a tractable mouse model for dissecting the hormonal and immunological pathways involved. And for the many other liver diseases in which sex differences in severity have been observed but poorly explained, from viral hepatitis to drug-induced injury, the message is that sex hormones deserve a central place in the analysis. The road from mouse to medicine is long, but this study marks a clear step toward understanding why, when hepatitis A strikes, men and women do not face equal odds.

Subject of Research: Sex differences in hepatitis A virus pathogenesis and the protective role of estrogen in mice

Article Title: Sex differences in hepatitis A virus infection in mice

Article References: Misumi, I., Shiota, I., Shiota, T., Zhao, J., Cullen, J. M., Lemon, S. M., & Whitmire, J. K. (2026). Sex differences in hepatitis A virus infection in mice. PLOS Pathogens, 22(10), e1014660. https://doi.org/10.1371/journal.ppat.1014660

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014660

Keywords: hepatitis A virus, sex differences, estrogen, liver injury, viral pathogenesis, interferon, immunopathology, ovariectomy, ESR1, hepatocytes, mouse model, PLOS Pathogens

Ferroptosis is unlike the better-known forms of programmed cell death such as apoptosis. Instead of the tidy cellular dismantling seen in apoptosis, ferroptosis is a violent, oxidative demise: iron catalyzes the peroxidation of lipids in cell membranes, causing them to rupture. Because liver tissue is rich in iron-handling machinery and constantly exposed to metabolic stress, it is particularly vulnerable. In diabetes, chronically elevated blood sugar floods cells with reactive oxygen species, depletes antioxidant defenses, and tips the delicate redox balance toward lipid peroxidation, making ferroptosis a plausible driver of diabetic liver injury.

To test whether stevia could intervene in this process, the team led by Zahra Amirahmadi of Islamic Azad University, Kazerun, together with colleagues at Shiraz University of Medical Sciences, induced diabetes in rats using streptozotocin, a chemical that destroys insulin-producing pancreatic beta cells. Twenty-four animals were randomly divided into four groups of six: healthy controls receiving water, diabetic rats receiving water, diabetic rats given an aqueous stevia extract at 400 milligrams per kilogram of body weight, and diabetic rats treated with metformin at 500 milligrams per kilogram, the standard first-line diabetes drug. After 28 days of daily dosing, the researchers measured blood chemistry, antioxidant capacity, inflammatory markers, the expression of ferroptosis-related genes, cell death by TUNEL assay, and liver tissue architecture.

The biochemical results were striking. Compared with untreated diabetic animals, stevia-treated rats showed significantly reduced fasting blood sugar, with the authors reporting a p-value below 0.01. The liver enzymes alanine aminotransferase and aspartate aminotransferase, both classic markers of hepatocyte damage, dropped substantially, indicating that the extract was protecting liver cells from injury. Body weight, which typically falls in uncontrolled diabetes, partially recovered in the stevia group. Meanwhile, the animals’ antioxidant defenses rebounded: total antioxidant capacity rose, and serum levels of the enzymes glutathione peroxidase, superoxide dismutase, and catalase all increased significantly, each with a p-value below 0.001.

Inflammation, another hallmark of diabetic liver disease, also receded. Levels of the inflammatory signaling molecules interleukin-6, C-reactive protein, tumor necrosis factor alpha, interleukin-1 beta, and the transcription factor NF-kappa-B were all lower in stevia-treated rats than in diabetic controls. This matters because inflammation and ferroptosis feed each other in a vicious cycle: dying cells release damage signals that recruit immune cells, which in turn produce reactive oxygen species that push neighboring cells toward ferroptosis. Breaking that loop at either end can blunt the entire cascade.

The most novel part of the study lies in the gene expression data. Stevia treatment upregulated GPX4, the glutathione peroxidase enzyme that sits at the very center of ferroptosis control by converting dangerous lipid peroxides into harmless lipid alcohols. It also boosted FTH1, the ferritin heavy chain that sequesters free iron and thereby removes the catalyst ferroptosis depends on, and SLC7, part of the system xc- cystine importer that supplies cells with the building blocks for glutathione, GPX4’s essential cofactor. All three genes are canonical suppressors of ferroptosis, and their coordinated upregulation suggests stevia acts on the pathway at multiple points rather than through a single target.

Histology and cell death assays corroborated the molecular story. TUNEL staining, which labels cells with fragmented DNA, revealed significantly fewer dying cells in the livers of stevia-treated diabetic rats, and microscopic examination showed improved tissue morphology compared with the disorganized, damaged architecture of untreated diabetic livers. Malondialdehyde, a breakdown product of lipid peroxidation and a direct chemical fingerprint of ferroptotic damage, was significantly reduced. Taken together, the data sketch a coherent mechanism: stevia restores antioxidant capacity, sequesters iron, repairs the glutathione supply line, and thereby prevents the membrane lipid destruction that defines ferroptosis.

The study is not without caveats. It involved only 24 rats over 28 days, and the streptozotocin model produces a form of insulin-deficient diabetes that does not fully recapitulate the more common type 2 disease in humans. The authors measured gene expression rather than protein levels or enzyme activity for the ferroptosis regulators, and they did not use a ferroptosis-specific inhibitor to prove that the pathway is causally responsible for the observed protection. Dose translation is another open question: 400 milligrams per kilogram in a rat is a large intake relative to what a human would consume in sweetened beverages, and purified steviol glycosides used in commercial sweeteners differ chemically from whole aqueous extract.

Even so, the work fits into a growing body of evidence linking plant-derived compounds to ferroptosis control. Previous studies have shown that polyphenols such as kaempferol, naringenin, and curcumin can suppress ferroptosis through the Nrf2 antioxidant pathway, and earlier work by the same Shiraz group found that stevia extract alleviates endoplasmic reticulum stress in diabetic rat livers. Other research has demonstrated that synthetic steviol derivatives protect against cardiomyopathy by inhibiting ferroptosis, and that stevia can prevent experimental liver cirrhosis by modulating profibrotic pathways. The new study extends this literature by explicitly connecting stevia to the ferroptosis machinery in diabetic liver injury.

For now, the practical takeaway is cautious. Stevia remains a safe, calorie-free sweetener with an expanding portfolio of documented biological activities, and this study strengthens the case that its polyphenol-rich extract carries genuine pharmacological potential. But rat data at high doses do not justify treating diabetes-related liver disease with sweetener packets, and human clinical trials would be needed before any therapeutic claims could be made. What the research does offer is a mechanistic roadmap: if ferroptosis is a driver of diabetic complications, then identifying safe dietary compounds that switch the pathway off, as this stevia extract appears to do in rats, could open a new front in the fight against the metabolic disease epidemic.

Subject of Research: Protective effects of aqueous Stevia extract against ferroptosis-mediated liver damage in streptozotocin-induced diabetic rats

Article Title: Regulating ferroptosis: the impact of stevia on alleviating liver damage in streptozotocin-induced diabetic rats

Article References: Amirahmadi, Z., Raeisi, A., Koohpeyma, F., Moghadam, D., Kiani, R., Jamshidi, S., Shams, F., Naeimi, S., & Dastghaib, S. (2026). Regulating ferroptosis: the impact of stevia on alleviating liver damage in streptozotocin-induced diabetic rats. Molecular Biology Reports, 53(1), Article 1686. https://doi.org/10.1007/s11033-026-12804-9

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12804-9

Keywords: stevia, ferroptosis, diabetes, liver injury, streptozotocin, GPX4, oxidative stress, antioxidants, inflammation, ferritin, lipid peroxidation, metformin

To understand why this matters, it helps to picture the two signaling complexes that form after TNF binds its receptor, TNFR1. At the plasma membrane, TNFR1 recruits RIPK1 through its death domain to build complex I, a platform that activates the IKK/NF-κB and MAPK pathways and thereby promotes cell survival and inflammatory gene transcription. When complex I is destabilized, RIPK1 can instead nucleate cytosolic complexes: complex IIa, containing RIPK1, FADD and caspase 8, which drives apoptosis; or, when caspase 8 is inhibited, complex IIb, the RIPK1–RIPK3 necrosome that initiates necroptosis, a lytic form of cell death in which activated RIPK3 phosphorylates MLKL, sending it to the plasma membrane to rupture the cell. RIPK1 is a component of all these assemblies, but the biochemical event that converts it from a prosurvival scaffold in complex I into a prodeath kinase in complex II has remained elusive.

The search began with an unbiased genetic approach. The team, led by Haohao Lu and Tongde Du in the laboratory of Sudan He at the Suzhou Institute of Systems Medicine, together with She Chen and Henning Walczak, conducted a CRISPR–Cas9 screen in human HT-29 colon cancer cells using a guide RNA library targeting genes encoding ubiquitin E3 ligases, deubiquitinating enzymes and other ubiquitination-associated proteins. The cells were challenged with a necroptosis-inducing cocktail of TNF, a Smac mimetic and the pan-caspase inhibitor z-VAD, a combination known as TSZ. After four rounds of selection, the single guide RNA targeting HERC4 emerged as the most enriched hit among all the E3 ligases and deubiquitinases tested, marking the enzyme as a prime suspect in the cell death machinery.

Validation followed swiftly across cell types. HERC4-knockout lines generated in HT-29, LS 174T, THP-1 and Jurkat cells all showed marked resistance to necroptosis, surviving doses of TSZ that killed their wild-type counterparts. Reintroducing HERC4, even at subphysiological levels, restored sensitivity to the death stimulus. Crucially, the loss of HERC4 did not merely blunt a downstream effector: phosphorylation of RIPK1, RIPK3 and MLKL, the sequential activations that define the necroptosis pathway, were all significantly reduced in HERC4-deficient cells. MLKL oligomerization and its translocation to the plasma membrane, the final steps before necroptotic rupture, were likewise suppressed. The same protection appeared in mouse embryonic fibroblasts and in a second necroptosis model using a TAK1 inhibitor, establishing HERC4 as a driver acting upstream of the canonical RIPK1–RIPK3–MLKL axis in both human and mouse cells.

Because HERC4 is a ubiquitin ligase, the next question was which protein it decorates. Coexpression experiments showed that HERC4 increased polyubiquitination of RIPK1 but not of RIPK3. Using mutant ubiquitin restricted to single linkage types, the researchers found that HERC4 specifically catalyzes K63-linked chains, a modification classically associated with signal transduction rather than protein degradation, and indeed HERC4-mediated ubiquitination did not lead to RIPK1’s destruction. In vitro assays with recombinant proteins confirmed that HERC4 directly ubiquitinates RIPK1, and mapping experiments showed that the intermediate domain of RIPK1 binds the HECT domain of HERC4, the region that carries the ligase’s catalytic activity.

Mass spectrometry then pinpointed the exact modification site. Among the ubiquitinated peptides recovered from RIPK1, one, EubKVYQMLQK, appeared exclusively when HERC4 was present and was absent with a catalytically inactive HERC4 mutant. The fragmentation spectrum unmasked lysine 627 on human RIPK1 as the ubiquitination site, a residue within the death domain that is highly conserved across species and corresponds to K612 in the mouse protein. This was a striking finding, because earlier work had shown that substituting this very lysine prevents TNF-induced cell death, hinting that ubiquitination there might be a necessary licensing step. A catalytically inactive HERC4 mutant, engineered on the basis of AlphaFold3 predictions by mutating H1023, C1025 and D1030, still bound RIPK1 but could no longer ubiquitinate it, and cells expressing this mutant were markedly resistant to necroptosis, proving that the ligase activity itself is what matters.

The mechanism that emerges is elegant and precise. HERC4 does not act indiscriminately: its interaction with RIPK1 occurs only under apoptotic or necroptotic stimulation, not with TNF alone, and is abolished by the RIPK1 kinase inhibitor necrostatin 1s. The team showed that HERC4 selectively recognizes RIPK1 that has been autophosphorylated at serine 166, the hallmark of RIPK1 kinase activation, since an S166A mutant lost the interaction while phosphomimetic S166D and S166E variants enhanced it. Sequential immunoprecipitation of the TNFR1 signaling complexes revealed that HERC4 is absent from membrane-bound complex I and instead binds complex I-derived, S166-phosphorylated RIPK1 once it has been released into the cytosol. There, HERC4’s K63-linked ubiquitination of the death domain enables RIPK1 to oligomerize, both with itself and with FADD, nucleating the assembly of complex IIa and, when caspases are blocked, the RIPK1–RIPK3 necrosome. Gel-filtration analysis confirmed that intact HERC4, but not the catalytic mutant, permits the formation of high-molecular-weight complexes containing phosphorylated RIPK1, RIPK3, MLKL and caspase 8.

Importantly, HERC4’s role is confined to the death arm of TNF signaling. The enzyme is dispensable for NF-κB activation: HERC4 knockout left phosphorylation of P65, IκBα, TAK1 and IKKα/β untouched, and it did not alter RIPK1 ubiquitination at K377, the cIAP1/2-mediated modification in complex I that supports survival signaling. This separation is what makes HERC4 so attractive as a drug target. Blocking it would, in principle, disarm TNF’s lethal potential while leaving its beneficial inflammatory and prosurvival functions intact, an effect similar to direct RIPK1 kinase inhibition but achieved one step upstream, at the licensing event itself.

The in vivo evidence is compelling. Mice lacking HERC4 were born and bred normally, indicating the protein is not essential for development. But when challenged with an overdose of TNF, a model of systemic inflammatory response syndrome, all wild-type littermates succumbed within 28 hours, whereas 80 percent of HERC4-deficient mice survived. The protected animals showed lower serum IL-6, reduced caspase 3 and PARP cleavage in the intestine, less cecal tissue damage on histology, and markedly reduced RIPK1 autophosphorylation. In a second model of acute liver injury induced by TNF and D-galactosamine, nearly all wild-type mice reached humane endpoints within four to six hours, while more than 70 percent of HERC4-deficient mice survived, with lower ALT and AST liver enzymes, reduced IL-6, suppressed hepatic caspase 3 activation and diminished histological damage.

The discovery resolves a long-standing conundrum in cell death biology: why RIPK1’s kinase activity, whose only known substrate is RIPK1 itself, is essential for TNF-induced death. The answer is that autophosphorylation at S166 creates the molecular tag that HERC4 recognizes, and HERC4’s ubiquitination of the death domain is what converts the phosphorylated kinase into a competent nucleator of the death complexes. Beyond inflammatory diseases such as SIRS, colitis and liver injury, the finding may reach into oncology, where necroptosis’s immunogenic nature has been proposed as a way to stimulate antitumor immunity, and where HERC4 has previously been implicated as a tumor suppressor. By supplying RIPK1 with what the authors call its license to kill, HERC4 now stands as both a mechanistic keystone of TNF signaling and a promising target for diseases driven by aberrant cell death.

Subject of Research: HERC4-mediated ubiquitination of RIPK1 as the molecular switch initiating TNF-induced cell death and inflammation

Article Title: HERC4-mediated ubiquitination licenses RIPK1 to initiate TNF-induced cell death

Article References: Lu, H., Du, T., Li, L., Cao, D., Li, K., Liu, L., Li, R., Yu, X., Hou, S., Wang, X., Shi, M., Liu, Y., Ma, F., Chen, S., Walczak, H., & He, S. (2026). HERC4-mediated ubiquitination licenses RIPK1 to initiate TNF-induced cell death. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-026-01871-y

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01871-y

Keywords: HERC4, RIPK1, TNF, ubiquitination, necroptosis, apoptosis, RIPK3, MLKL, inflammation, E3 ligase, liver injury, cell death signaling

Sepsis remains one of the leading causes of death in children worldwide, arising when an infection triggers a dysregulated immune response that damages the body’s own organs. In adults, clinicians have long recognized that the liver is both a victim and a signal in this process. Hepatic dysfunction in adult sepsis is considered an independent predictor of mortality, meaning that even after accounting for other factors, a failing liver marks a patient at elevated risk. Whether the same holds true for children, however, had never been systematically examined. Individual pediatric studies had reported varying rates of liver injury and conflicting associations with death, but no one had pooled the data. The Indonesian team registered their review prospectively with PROSPERO under the identifier CRD420261387360 and searched five major databases, including PubMed, Scopus, MEDLINE via EBSCO, the Cochrane Library, and ClinicalTrials.gov, from their inception through 21 May 2026, without language restrictions. Notably, Embase was not searched, a limitation the authors acknowledge.

The eligibility criteria were strict. Studies had to enroll children aged one month to 18 years, define sepsis according to consensus criteria, and report outcomes stratified by the presence or absence of liver injury. Two reviewers independently screened records and extracted data, a standard safeguard against individual error. Risk of bias was evaluated using two prespecified instruments: the Newcastle-Ottawa Scale for the observational studies included in the mortality analysis and the Quality in Prognosis Studies tool, known as QUIPS, which is specifically designed for prognostic research. Statistical pooling employed a Mantel-Haenszel random effects model for mortality odds ratios, while the proportion of children developing liver injury was estimated with a logistic-normal generalized linear mixed model, an approach better suited to proportions than naive averaging. Certainty of the evidence was graded using GRADE, the framework that rates confidence in findings from high to very low.

After screening, ten studies made the final cut. The headline result came from five of these studies, encompassing 1,717 children, that reported mortality according to liver injury status. Pooling their unadjusted data, the researchers found that children with SALI had nearly four times the odds of dying compared with those without it, with an odds ratio of 3.88 and a 95 percent confidence interval of 2.21 to 6.80. Three of the studies measured death during hospital admission, one measured death in the pediatric intensive care unit, and one did not specify the timing. On the surface, this is a striking signal: a liver under assault during sepsis appears to mark a child in grave danger.

But the statistical fine print tells a more cautious story. The prediction interval, which estimates the range of true effects one might expect in future studies, stretched from 0.63 to 23.80, crossing the value of 1.0 that would indicate no association at all. In other words, some future pediatric population might show no link between liver injury and death, while another might show an enormous one. The Hartung-Knapp adjusted confidence interval, a more conservative calculation that accounts for uncertainty in the between-study variance, widened further to 1.65 to 9.12. Combined with a GRADE rating of very low certainty, these numbers mean clinicians should treat the fourfold figure as a hypothesis-generating signal rather than a settled fact. The heterogeneity across studies, likely driven by different definitions of liver injury, different patient populations, and different measurement schedules, is substantial enough to temper any confident clinical claim.

The deeper problem is confounding by severity. Children whose livers fail during sepsis are, almost by definition, sicker than children whose livers hold out. Two of the included studies attempted to address this statistically. Saini and colleagues reported that SALI remained associated with mortality after adjustment for selected clinical covariates, but their mortality model did not include pSOFA, the pediatric Sequential Organ Failure Assessment score, or any other validated global severity measure. Without such a score, it is impossible to know whether the liver adds information beyond what general illness severity already captures. Only Koca and colleagues adjusted hepatic markers for validated pediatric severity scores, namely PRISM III, the Pediatric Risk of Mortality Score, and PELOD-2, the Pediatric Logistic Organ Dysfunction Score. In that analysis, neither alanine aminotransferase, the enzyme ALT commonly used to detect liver cell damage, nor total bilirubin, the pigment that accumulates when the liver fails to clear it, remained independently associated with death. Once a child’s overall severity was accounted for, the liver’s apparent prognostic power evaporated.

Beyond mortality, the review also estimated how often liver injury occurs in pediatric sepsis at all. Across seven studies covering 1,876 children, the pooled proportion was 29 percent, with a wide 95 percent confidence interval of 17 to 46 percent. That range is itself informative: it reveals how inconsistently SALI is defined and detected across the pediatric literature. Some studies may rely on a single elevated transaminase value, others on bilirubin thresholds, and still others on composite criteria, and the timing of measurement during the septic episode varies just as widely. The authors argue that this heterogeneity makes a strong case for standardized pediatric definitions of sepsis-associated liver injury and for agreed ascertainment schedules, so that future studies measure the same thing at the same moments. The Pediatric Organ Dysfunction Information Update Mandate, or PODIUM, represents one ongoing effort to bring consistency to organ dysfunction definitions in pediatric critical care.

The review also examined candidate biomarkers that might identify liver injury or predict outcomes earlier than conventional tests. The most promising was APRI, the AST-to-platelet ratio index, a simple calculation combining aspartate aminotransferase levels with platelet counts. In two cohorts, APRI showed areas under the receiver operating characteristic curve, or AUROCs, of 0.83 to 0.89, values generally considered good discriminative ability. Yet the authors urge caution on two fronts. First, the diagnostic thresholds differed substantially between the two cohorts, meaning a child classified as having liver injury by one study’s cutoff might be classified as normal by another’s. Second, the APRI is built on AST, while the outcome definitions in these studies were based on ALT, creating an overlap problem that limits how the biomarker’s performance can be interpreted. Other markers examined in the underlying studies, including lactate dehydrogenase, apolipoprotein A-V, and the albumin-corrected anion gap, remain at even earlier stages of evaluation. The authors conclude that no candidate biomarker is ready for clinical use without prospective multicenter validation.

What does this mean for the pediatric intensivist at the bedside? The practical takeaway is nuanced. An elevated ALT or bilirubin in a septic child should certainly prompt attention, and the unadjusted association suggests these children warrant heightened vigilance. But the evidence does not yet support treating liver injury as an independent prognostic marker that adds value beyond established severity scores such as PRISM III, PELOD-2, or pSOFA. The honest answer to whether hepatic dysfunction carries prognostic information of its own is that nobody currently knows, and the review makes that uncertainty explicit rather than papering over it. This kind of transparency is increasingly valued in evidence-based medicine, where overconfident meta-analytic estimates can mislead practice as surely as absent evidence can.

The study, published open access on 7 October 2026 and available under a Creative Commons license, received no external funding and its authors declare no competing interests. Its limitations are clearly stated: only ten studies were available, Embase was not searched, adjusted analyses were rare, and the underlying literature is dominated by observational designs vulnerable to confounding. The research team, which also included Ade Gautama and Khanyfah Syagita, notes with gratitude that Dr. Abdulkerim Elmas provided unpublished subgroup data through personal correspondence, strengthening the primary mortality analysis. For now, the review stands as both a warning and a roadmap: liver injury during pediatric sepsis is common, appears dangerous, and demands rigorous, standardized study before it can be woven into the scoring systems that guide care for the world’s sickest children.

Subject of Research: Sepsis-associated liver injury and mortality outcomes in children

Article Title: Sepsis-associated liver injury and clinical outcomes in children: a systematic review and meta-analysis

Article References: Wiriadinata, N. E. R., Gautama, A., Syagita, K., & Oswari, H. (2026). Sepsis-associated liver injury and clinical outcomes in children: a systematic review and meta-analysis. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07775-6

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07775-6

Keywords: sepsis, liver injury, pediatrics, meta-analysis, mortality, PICU, biomarkers, APRI, PRISM III, PELOD-2, pSOFA, systematic review

Cholestasis arises when the delicate plumbing of the liver fails. Bile, a detergent-like fluid produced by hepatocytes to carry away cholesterol, toxins, and metabolic waste, must be exported through a series of specialized transporter proteins embedded in the canalicular membrane of liver cells. When that export system breaks down, bile acids back up inside hepatocytes, where their detergent properties become a weapon against the very cells that produce them. The result is oxidative stress, inflammatory signaling, programmed cell death, and eventually fibrosis. Among the transporters involved, the bile salt export pump, known as BSEP, occupies a central position. It is the primary efflux pump for conjugated bile acids, and its dysfunction is widely regarded as a key initiating event in cholestatic liver damage, whether the cause is a genetic mutation, a drug side effect, or a chemical insult.

To model this injury experimentally, the researchers turned to alpha-naphthyl isothiocyanate, or ANIT, a compound long used to induce intrahepatic cholestasis in laboratory animals. ANIT damages the biliary epithelium and disrupts canalicular transport, producing a cascade of biochemical and histological changes that closely mirror human cholestatic disease. Sixty male Sprague Dawley rats were randomly assigned to five experimental groups: a healthy control group, a group receiving ANIT alone, two groups pretreated with selenium at doses of 0.5 and 1 milligram per kilogram of body weight before ANIT exposure, and a group receiving selenium alone to assess the element’s intrinsic safety profile at these doses.

The damage inflicted by ANIT was comprehensive. The researchers documented marked suppression of BSEP, along with two other critical transporters, MRP2 and NTCP, which together coordinate the import and export of bile acids and their metabolites across hepatocyte membranes. Simultaneously, the expression of genes governing bile acid synthesis and detoxification, including CYP7A1, UGT1A1, and the nuclear receptor FXR that orchestrates much of bile acid homeostasis, was thrown into disarray. These molecular disruptions translated into measurable clinical harm: serum markers of cholestasis and liver injury climbed, oxidative stress intensified, inflammatory signaling pathways were activated, and hepatocytes underwent increased apoptosis. Under the microscope, liver tissue showed pronounced histopathological injury and early fibrotic changes, confirming that the model had faithfully reproduced the destructive arc of cholestatic disease.

Selenium pretreatment changed that picture dramatically, but only at the higher dose. At 1 milligram per kilogram, the element significantly attenuated ANIT-induced damage across nearly all biochemical, molecular, and histopathological endpoints examined. Bile acid transporter expression was preserved, the balance of bile acid synthesis and detoxification was rebalanced, and the downstream consequences of transporter failure, including oxidative damage, inflammation, and cell death, were substantially blunted. By contrast, the lower dose of 0.5 milligrams per kilogram produced only partial improvements, and for several key parameters, including serum ALT, AST, GGT, and bilirubin levels as well as oxidative and inflammatory markers, the differences relative to the ANIT-only group did not reach statistical significance. This dose-dependence is a critical finding, suggesting that selenium’s protective window in this context is narrower than a simple more-is-better assumption might imply.

Delving into the signaling mechanisms, the team found that the protective effect was accompanied by activation of the NRF2/HO-1 axis, one of the cell’s master antioxidant defense systems, and by stimulation of Sirt1, a nutrient-sensing deacetylase with well-established roles in cellular stress resistance and metabolic regulation. At the same time, selenium suppressed inflammatory signaling mediated by TLR4 and the transcription factor NF-κB, a pathway that ANIT exposure had strongly activated. Perhaps most intriguingly, the researchers observed reactivation of PI3K/AKT/mTOR-dependent pro-survival signaling, suggesting that selenium did not merely mop up reactive oxygen species but actively shifted hepatocytes from a death-oriented to a survival-oriented signaling state. Together, these pathways form a coherent mechanistic narrative in which selenium stabilizes the liver’s bile acid export machinery while simultaneously fortifying its defenses against the oxidative, inflammatory, and apoptotic fallout of cholestatic stress.

The study also incorporated complementary computational analyses that provided structural support for the biological findings. Molecular docking experiments indicated that ANIT forms stable interactions within the inhibitory binding pocket of BSEP, consistent with the idea that the chemical directly interferes with the pump’s function. This structural insight is significant because BSEP inhibition has become a major concern in pharmaceutical development; drug candidates that block the pump are frequently flagged for cholestatic risk, and regulatory agencies and the International Transporter Consortium have emphasized BSEP inhibition testing as a tool for predicting liver injury liability. By anchoring the ANIT model to a structurally plausible mechanism of BSEP interference, the study strengthens the relevance of the selenium protection data to broader questions of drug-induced cholestasis.

Selenium itself is a fascinating and double-edged nutrient. As an essential trace element, it is incorporated into selenoproteins, including the glutathione peroxidases and thioredoxin reductases that form the biochemical backbone of antioxidant defense. Prior research has documented protective effects of selenium against oxidative injury in the kidney, the nervous system, and the liver in various toxicological models, and recent work has linked dietary selenium to amelioration of fatty liver disease through the KEAP1/NRF2 pathway. Yet the element also has a well-defined toxic threshold. The European Food Safety Authority has established a tolerable upper intake level for selenium, and excess intake can itself produce oxidative stress and selenosis. The dose-dependence observed in the current study, in which half the effective dose failed to confer significant protection, underscores that selenium biology is not a simple linear relationship between intake and benefit.

The authors are careful to frame their findings as evidence for a prophylactic rather than a therapeutic role. In the experimental design, selenium was administered before ANIT exposure, meaning the element was present in liver tissue before the cholestatic insult began. This pretreatment strategy allowed selenium to prime antioxidant defenses and stabilize transporter expression ahead of injury, but it does not demonstrate that selenium could reverse established cholestasis. For patients already suffering from cholestatic liver disease, whether from biliary obstruction, drug toxicity, or autoimmune conditions, the study does not yet provide a basis for selenium as a treatment. What it does provide is a proof of principle that maintaining hepatic redox homeostasis and BSEP expression before an insult can dramatically reduce the severity of the resulting injury.

The implications extend in several directions. For clinicians and nutrition scientists, the work adds hepatobiliary protection to the growing list of selenium-dependent health benefits, while reinforcing the importance of adequate but not excessive selenium status. For toxicologists and drug developers, the detailed mapping of the BSEP-FXR-centered protective network offers a mechanistic template for evaluating candidate cholestasis-preventing compounds. And for basic researchers, the study highlights the intricate interplay between bile acid transport, redox signaling, inflammatory pathways, and cell survival machinery that determines whether a stressed liver recovers or spirals into fibrosis. As cholestatic liver diseases continue to impose a substantial clinical burden worldwide, the humble trace element that helps glutathione peroxidase neutralize peroxides may prove to be an unexpectedly powerful ally, provided the dose, the timing, and the therapeutic window are respected with the precision this new research demands.

Subject of Research: Selenium pretreatment and protection against ANIT-induced cholestatic liver injury via BSEP preservation and redox homeostasis

Article Title: Selenium pretreatment alleviates ANIT-induced cholestasis by preserving BSEP expression and hepatic redox homeostasis

Article References: Bolat, İ., Özdemir, S., Çomakli, S., Sağlam, Y. S., Tekin, S., Çinar, B., Bolat, M., Orhan, B., Sağsöz, M. E., & Okkay, U. (2026). Selenium pretreatment alleviates ANIT-induced cholestasis by preserving BSEP expression and hepatic redox homeostasis. Molecular Biology Reports, 53(1), Article 1658. https://doi.org/10.1007/s11033-026-12849-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12849-w

Keywords: selenium, cholestasis, BSEP, ANIT, liver injury, oxidative stress, FXR, NRF2, bile acid transporters, NF-kB, hepatoprotection, rats

The central finding of the study is that heat stress reshapes the gut microbiome of mice in two complementary ways. First, the microbial disruption is accompanied by increased levels of lipopolysaccharide, or LPS, a potent inflammatory molecule embedded in the outer membrane of many gut bacteria. When the intestinal barrier weakens, LPS can slip into the bloodstream and activate immune cells throughout the body. Second, the team found that heat stress enhances microbial catabolism of arginine, an amino acid that the new work identifies as a natural brake on inflammatory signaling. In other words, heat does not just add fuel to the inflammatory fire; it removes one of the fire extinguishers at the same time.

To establish that these microbial changes are not merely a byproduct of heat injury but an active driver of it, the researchers performed fecal microbiota transplantation experiments. When they transferred gut microbes from heat-stressed mice into healthy recipient animals, the recipients went on to mount exaggerated inflammatory responses after experiencing heat stress themselves. This result provides some of the strongest causal evidence yet that the gut microbial alterations induced by heat are functionally responsible for worsening systemic inflammation, rather than simply correlating with it. It suggests that the microbiome acts as an intermediary that can be reprogrammed by environmental temperature and then transmit that reprogramming into immune consequences.

The mechanistic heart of the paper concerns how arginine protects tissues at the molecular level. Using cell culture experiments in macrophage-like RAW264.7 cells and microglial BV2 cells, the team showed that arginine reduces the abundance of MyD88, a key adaptor protein that sits at the crossroads of multiple innate immune signaling pathways. MyD88 physically interacts with Toll-like receptor 4, the receptor that recognizes LPS, and passes the alarm signal onward to the transcription factor NF-kB, whose p65 subunit must move into the nucleus to switch on genes encoding pro-inflammatory cytokines. The researchers found that arginine promotes ubiquitination of MyD88, the molecular tag that marks proteins for degradation, thereby lowering MyD88 protein levels. With less MyD88 available, the interaction between MyD88 and TLR4 weakens, p65 nuclear translocation is curtailed, and the expression of pro-inflammatory genes falls.

Experiments in living mice reinforced this mechanism. Pretreating animals with exogenous arginine significantly suppressed inflammation in the liver and in the cortex of the brain after heat stress, the two organs highlighted in the study as major sites of heat-related damage. When the researchers knocked down TLR4 or MyD88 in their cellular models, the protective effect of arginine was lost or blunted, indicating that the amino acid’s benefit depends on the very pathway it modulates. Taken together, the data sketch a coherent circuit: heat raises LPS and lowers arginine, LPS engages TLR4, and the resulting MyD88-dependent signaling cascade runs unchecked when arginine is scarce.

Importantly, the team did not stop at animal models. They examined serum samples from patients suffering from heatstroke and found that arginine levels were lower in these patients than expected. Moreover, the degree of arginine depletion was positively related to markers of liver injury and inflammation, meaning that patients with the least circulating arginine tended to show the worst clinical indicators. While the human component of the study is observational and cannot by itself prove causation, it aligns closely with the mouse and cellular data and raises the possibility that arginine status could serve as a biomarker for heatstroke severity or as a guide for nutritional intervention.

The translational ambition of the work culminates in a delivery system the authors developed to counteract the microbial imbalance: an arginine-enriched oral inulin hydrogel, abbreviated Arg_OIH. Inulin is a dietary fiber with prebiotic properties, meaning it can nourish beneficial gut microbes and help maintain microbial homeostasis. By embedding arginine within an inulin-based hydrogel, the researchers aimed to achieve two goals at once. The inulin component stabilizes the gut microbiota, which in turn reduces LPS levels, while the hydrogel matrix provides a sustained, slow release of arginine to keep the amino acid available to tissues over time rather than delivering a single spike that the body would quickly clear.

According to the study, this hydrogel formulation was able to prevent the inflammatory responses exacerbated by heat-induced gut microbial alterations, and the supplementary data document its characterization, its effects on the gut microbiota of heat-stressed mice, and histopathological evidence of tissue protection. The authors also compared the hydrogel against a simple oral arginine solution, suggesting that the sustained-release design offers advantages over free amino acid supplementation. If the approach can be translated safely to humans, it could offer a practical prophylactic strategy for vulnerable populations, such as outdoor workers, athletes, the elderly, and people living in regions where extreme heat events are becoming routine.

The study also carries broader conceptual weight for microbiome science. It adds to a growing body of evidence that the gut microbiome functions as a metabolic buffer between the environment and the immune system, converting external stressors into shifts in microbial chemistry that either calm or inflame the host. Here, the balance between LPS and arginine emerges as a previously underappreciated axis: one side pushes TLR4-MyD88 signaling toward inflammation, while the other restrains it through post-translational modification of a central adaptor protein. Disrupting that balance, as heat stress appears to do, converts a manageable physiological response into a self-amplifying inflammatory loop capable of damaging multiple organs.

Caveats remain, as they do in any preclinical study. The mouse models of heat stress, however carefully controlled, cannot fully reproduce the complex physiology of human heatstroke, and the clinical samples, while suggestive, came from a patient cohort whose characteristics are detailed in the study’s supplementary tables. The authors note that the published version was shared early as accepted peer-reviewed research, subject to final editorial processing. Nevertheless, the convergence of evidence across fecal transplantation, metabolomics, cellular signaling assays, genetic knockdown experiments, and human serum measurements gives the arginine-MyD88 axis a solid evidentiary foundation. As global temperatures continue their upward climb, interventions that restore gut microbial balance and replenish protective metabolites may become an increasingly important part of the public health arsenal against heat, and this study offers a concrete, mechanistically grounded starting point for developing them.

Subject of Research: Gut microbial arginine catabolism and LPS balance in heat stress-induced inflammatory responses

Article Title: Heat stress enhances gut microbial arginine catabolism to amplify MyD88-dependent inflammatory responses

Article References: Ye, X., Cai, Q., Pan, Y., Xu, M., Li, Y., You, M., Yang, J., Chen, S., He, H., Hong, G., & Zheng, H. (2026). Heat stress enhances gut microbial arginine catabolism to amplify MyD88-dependent inflammatory responses. Microbiome, 14(1), Article 215. https://doi.org/10.1186/s40168-026-02514-6

Image Credits: AI Generated

DOI: 10.1186/s40168-026-02514-6

Keywords: heat stress, gut microbiota, arginine, lipopolysaccharide, MyD88, TLR4, inflammation, heatstroke, inulin hydrogel, NF-kB, liver injury, metabolomics

The compound at the center of the research is puerarin, an isoflavone extracted from the root of the kudzu vine, a plant long used in traditional Chinese medicine. Puerarin has already attracted attention for its antioxidant and anti-inflammatory properties, and previous studies have linked it to protection of heart, brain, and liver tissue. The problem is that puerarin is a notoriously difficult drug to deliver. It dissolves poorly in water, degrades quickly in the body, and is metabolized so rapidly that very little of an oral dose ever reaches target tissue. These pharmacokinetic weaknesses have kept it out of mainstream clinical use despite two decades of promising laboratory data.

To overcome that barrier, a team of researchers from Saudi Arabia and Egypt, led by Shaza Alyamani of Batterjee Medical College and Gehad Elshopakey of Mansoura University, encapsulated puerarin inside nanoparticles made of poly(lactic-co-glycolic acid), or PLGA, a biodegradable polymer already approved by regulators for use in drug delivery and medical devices. The resulting particles were remarkably uniform: roughly 69 nanometers in diameter on average, with individual particles ranging between 46 and 65 nanometers, a narrow size distribution, and a strongly negative surface charge that keeps them from clumping together. Using a modified nanoprecipitation and solvent evaporation technique, the team achieved an encapsulation efficiency of about 84 percent and a drug loading of 8.5 percent, meaning the tiny particles carry a substantial cargo of the active compound.

Laboratory release tests revealed why the formulation matters so much. Free puerarin dumped nearly all of its payload within 24 hours in a burst that would be wasted in the bloodstream. The PLGA-encapsulated version released only about 8 percent initially and then trickled out steadily, reaching roughly 52 percent at 12 hours and about 91 percent over 72 hours. That sustained profile means the drug stays in circulation longer, and Fourier transform infrared spectroscopy confirmed that puerarin and the polymer interact only through non-covalent forces, preserving the chemical integrity of both components.

With the formulation validated, the researchers turned to an animal model of arsenic poisoning. Sixty male Sprague-Dawley rats were randomly divided into six groups. One group served as untreated controls, two groups received free puerarin or the nanoparticle formulation alone, one group received arsenic at 10 milligrams per kilogram of body weight orally for 14 days to induce subacute liver injury, and two groups received arsenic alongside either free puerarin or the nanoformulation at an equivalent dose of 100 milligrams per kilogram. The study was designed with a formal power analysis and followed international ethical standards for animal research, including OECD guidelines and ARRIVE recommendations.

The arsenic-only animals showed all the classic signatures of a poisoned liver. Serum levels of the liver enzymes ALT, AST, and ALP surged, indicating that hepatocyte membranes had ruptured and leaked their contents into the blood. Albumin and total protein dropped, reflecting a failing synthetic capacity, and the lipid profile deteriorated in a pattern consistent with mitochondrial dysfunction. At the molecular level, the picture was even more striking. Arsenic exposure flooded liver cells with reactive oxygen species, oxidized DNA, as measured by the marker 8-OHdG, and drove iron accumulation. Crucially, the rats’ livers showed a coordinated collapse of the antioxidant machinery that normally guards against a recently recognized form of cell death called ferroptosis, an iron-dependent process in which lipid membranes are destroyed by runaway peroxidation. The ferroptosis-suppressing proteins GPX4 and SLC7A11 were sharply downregulated, while the pro-ferroptotic enzymes ACSL4 and transferrin receptor 1 climbed, alongside mounting levels of lipid peroxidation products such as MDA and 4-HNE.

Both forms of puerarin pushed back against this molecular storm, but the nanoparticle version did so more decisively. PU-PLGA treatment restored the SLC7A11/GPX4 axis, boosted nuclear levels of the master antioxidant regulator NRF2, slashed hepatic iron, and normalized markers of lipid peroxidation to near-control values. It also quieted the inflammatory cascade, suppressing NF-κB signaling and lowering the cytokines TNF-α, IL-6, and IL-1β, along with the enzyme COX-2. Fibrotic signaling, marked by TGF-β and collagen type I, retreated as well. The nanoformulation outperformed free puerarin on nearly every measure, and the differences between the two treatments were statistically significant for most biomarkers, including NRF2, GPX4, ACSL4, TNF-α, and the fibrosis markers.

Perhaps most striking were the cell-death pathways. Arsenic tipped the apoptotic balance toward death by raising pro-apoptotic Bax and caspase-3 while depleting the survival proteins Bcl-2 and phosphorylated AKT. PU-PLGA reversed this imbalance, restoring anti-apoptotic signaling more effectively than the crude compound. The benefits were visible under the microscope, too. Light microscopy revealed that arsenic-treated livers suffered dilated sinusoids, hepatocyte vacuolation, and necrotic nuclei, while transmission electron microscopy showed swollen mitochondria with shattered cristae and dilated endoplasmic reticulum. In the nanoparticle-treated animals, hepatic architecture and mitochondrial ultrastructure were largely preserved, and immunohistochemistry confirmed robust restoration of GPX4 in hepatocytes alongside suppression of ACSL4 staining.

The authors are appropriately careful about interpretation. They note that the ferroptosis findings rely on ELISA-based biomarkers rather than direct functional validation with lipid-reactive-oxygen-species probes or ferroptosis inhibitors such as ferrostatin-1, so the data support ferroptosis-associated pathway modulation rather than definitive proof of ferroptotic cell death being blocked. Similarly, pharmacokinetic measurements of puerarin levels in blood and liver were not performed, so the superior performance of the nanoformulation, while plausibly attributable to sustained release and improved bioavailability, cannot yet be pinned to a specific mechanism. The study also used only male rats over a short two-week window, leaving questions of sex differences and long-term fibrosis progression open for future work.

Even with those caveats, the study is a compelling demonstration of how nanotechnology can rescue a pharmacologically gifted but delivery-challenged natural product. By wrapping puerarin in biodegradable PLGA shells, the researchers achieved simultaneous suppression of oxidative stress, ferroptosis-related signaling, inflammation, apoptosis, and early fibrotic remodeling in a living model of arsenic hepatotoxicity. For the millions of people worldwide whose drinking water carries dangerous levels of arsenic, the work offers a proof of concept that a kudzu-derived isoflavone, delivered at the nanoscale, could one day become a genuinely protective therapy. Translational validation, safety profiling, and human pharmacokinetic studies remain the necessary next steps, but the groundwork is now firmly in place.

Subject of Research: Hepatoprotective effects of PLGA-loaded puerarin nanoparticles against arsenic-induced liver injury through modulation of ferroptosis and oxidative stress

Article Title: PLGA-loaded puerarin attenuates arsenic-induced liver injury through modulation of ferroptosis, oxidative stress, inflammation, and apoptotic signaling

Article References: Alyamani, S. A., Hifni, B. A., Alqahtani, N. S., Elmorsy, E. M., Al-Ghafari, A. B., Al Doghaither, H. A., Chatha, W. A., & Elshopakey, G. E. (2026). PLGA-loaded puerarin attenuates arsenic-induced liver injury through modulation of ferroptosis, oxidative stress, inflammation, and apoptotic signaling. BMC Pharmacology and Toxicology, 27(1), Article 129. https://doi.org/10.1186/s40360-026-01221-0

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01221-0

Keywords: puerarin, PLGA nanoparticles, arsenic, hepatotoxicity, ferroptosis, oxidative stress, Nrf2, GPX4, liver injury, nanomedicine, inflammation, apoptosis

To understand why this matters, it helps to start with the biology of oxidative stress. The liver is a metabolic furnace: its mitochondria, its NADPH oxidases, its inducible nitric oxide synthase, and its cytochrome P450 enzymes all generate reactive oxygen and nitrogen species as byproducts of detoxification and metabolism. Under healthy conditions, an elaborate antioxidant arsenal, including reduced glutathione, thioredoxin, superoxide dismutase, catalase, and peroxiredoxins, keeps these oxidants in check. The expression of much of this arsenal is coordinated by Nrf2, a transcription factor discovered in 1994. In resting cells, Nrf2 is continuously captured by its repressor Keap1 and shuttled to the proteasome for destruction. When oxidative or electrophilic stress modifies critical cysteine residues on Keap1, Nrf2 escapes degradation, translocates to the nucleus, and binds antioxidant response elements to switch on genes such as NQO1, heme oxygenase-1, and the glutathione-synthesis machinery. When this system fails, persistent oxidative damage drives apoptosis, necrosis, and inflammation, fueling diseases from cardiovascular pathology to cancer.

The review’s central insight is that Nrf2’s behavior is strikingly context-dependent across liver diseases. In alcoholic liver disease, chronic ethanol consumption induces CYP2E1, an enzyme that generates torrents of reactive oxygen species while metabolizing alcohol, creating a vicious cycle of oxidative injury. Upstream regulators such as the deacetylase SIRT6, the endoplasmic reticulum chaperone ERdj5, and the autophagy protein SNX10 all bolster Nrf2 signaling to counter this assault. In metabolic dysfunction-associated fatty liver disease, high-fat diets suppress autophagosome biogenesis through mTOR signaling, which stabilizes Keap1 and degrades Nrf2, leaving hepatocytes vulnerable to ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation. Yet Nrf2 activation in this setting is double-edged: it also upregulates lipid transporters such as CD36 and the very-low-density lipoprotein receptor, and promotes the lipogenic program of PPARγ, meaning that boosting Nrf2 can simultaneously protect against oxidative damage and worsen fat accumulation.

In acute drug-induced liver injury, exemplified by acetaminophen overdose, the stakes are starker. A small fraction of acetaminophen is converted by CYP2E1 into NAPQI, a highly reactive metabolite that exhausts glutathione stores and covalently damages mitochondrial proteins. Nrf2-knockout mice are far more susceptible to this injury than wild-type animals because they cannot replenish glutathione efficiently, and a cascade of regulators, from the deubiquitinase USP25 to the autophagy receptor p62 and the transcription factor TFEB, modulates how robustly Nrf2 responds. Despite decades of research, N-acetyl cysteine remains the only approved therapy for acetaminophen overdose, with a narrow therapeutic window and notable side effects, which is precisely why the review’s microbiome-focused angle has attracted attention. In hepatocellular carcinoma, the picture inverts entirely: transient Nrf2 activation suppresses tumor initiation, but constitutive activation in established tumors, often driven by p62 accumulation, TSPO, or TRIM25, promotes progression, immune escape, pseudohypoxia, and resistance to ferroptosis-inducing therapies such as sorafenib.

The heart of the review is its argument that the gut microbiota acts as an upstream driver of all of this hepatic Nrf2 activity. Because the liver is the first organ to receive portal blood, its Nrf2 signaling is perpetually bathed in microbial biochemical signals. Specific probiotic strains have now been shown to exploit this route. Lacticaseibacillus rhamnosus GG, one of the best-characterized probiotics, protects against alcoholic and drug-induced liver injury, and a landmark integrated metabolomics and transcriptomics study identified its metabolite 5-methoxyindoleacetic acid, a tryptophan derivative, as a direct activator of hepatic Nrf2 that induces antioxidant genes including NQO1, HMOX1, and GCLC. Intriguingly, the same metabolite has been linked to longevity in centenarian cohort studies. Bifidobacterium longum strains produce sedanolide and indole-3-lactic acid, both of which activate Nrf2 and its target genes, while Lachnospiraceae bacteria, whose loss is a hallmark of alcoholic liver disease, generate butyrate and N-acetyl-glutamic acid that engage Nrf2 and inhibit ferroptosis. Akkermansia muciniphila, depleted in patients with alcoholic liver disease, contributes short-chain fatty acids that maintain hepatic redox homeostasis.

These microbial metabolites fall into chemically distinct classes with convergent endpoints. Short-chain fatty acids such as acetate, propionate, and butyrate, fermented from dietary fiber, act through pathways including AMPK-ULK1-p62 signaling to induce both mitophagy and Nrf2-driven antioxidant transcription; butyrate has even been proposed as a synergistic partner for N-acetyl cysteine in acetaminophen poisoning. Tryptophan metabolites, particularly indole derivatives, operate largely through the aryl hydrocarbon receptor, which is coordinately regulated with Nrf2 in what the field calls the AhR-Nrf2 gene battery, protecting both the intestinal barrier and the liver itself. Urolithins, produced by gut bacteria from the ellagitannins abundant in pomegranates, activate Nrf2/ARE signaling and promote mitophagy, with urolithin A outperforming N-acetyl cysteine in preclinical head-to-head comparisons of dosing and therapeutic window. Bacterial exopolysaccharides scavenge free radicals directly while activating Keap1/Nrf2 pathways. Not all microbial chemistry is benign, however: trimethylamine N-oxide, derived from dietary choline and carnitine, suppresses Nrf2-mediated antioxidant responses and induces hepatic endoplasmic reticulum stress, underscoring that the microbiota’s influence is genuinely dual-edged.

Perhaps the most technically sophisticated section of the review concerns microbial enzymes, the molecular interface that converts inert dietary precursors into Nrf2 modulators. Beta-galactosidase from Lactobacillus vaginalis liberates the isoflavone daidzein from the diet, which then activates an AKT-GSK3β-Nrf2 pathway and inhibits ferroptosis in acetaminophen injury. A related enzyme from Rikenella microfusus promotes absorption of the isoflavone biochanin-A, boosting glutathione synthesis. Formate C-acetyltransferase in Bifidobacterium generates indole-3-carboxylic acid, which inactivates CYP2E1 itself, while phenyllactate dehydrogenase in Limosilactobacillus reuteri produces indole-3-lactic acid, which dampens NLRP3 inflammasome activation in macrophages. The authors frame this as a new research paradigm, moving microbiome science beyond simple probiotic-versus-pathogen attribution toward a systematic chain of microbiota, microbial enzyme, metabolite, and target protein, a logic that has recently extended to gut fungi and bacteriophages as well.

On the therapeutic front, the review surveys four intervention strategies. Prebiotics, particularly plant polysaccharides and polyphenols, selectively enrich beneficial bacteria and indirectly upregulate hepatic Nrf2, HO-1, and GCLC, with randomized trial evidence already supporting oligofructose in fatty liver disease. Fecal microbiota transplantation remodels the entire ecosystem, and animal studies show that donors pretreated with polyphenols or other compounds transfer SCFA-rich communities that promote hepatic Nrf2 nuclear translocation; clinical trials have demonstrated improved intestinal permeability in fatty liver disease and acceptable safety in alcohol-associated liver failure, though bacteraemia and other adverse events have been reported. Dietary interventions rich in fiber and polyphenols feed the Nrf2-activating metabolite pipeline, whereas Western-style diets promote dysbiosis and harmful metabolites. Finally, combining microbiome modulation with direct Nrf2 activators such as sulforaphane, which broccoli seed extract delivers alongside a bloom of Akkermansia and Lactobacillus, may produce synergistic hepatoprotection.

Substantial obstacles remain before the gut-microbiota-Nrf2 axis reaches the clinic. Interindividual variability is profound: fiber supplementation reliably raises short-chain fatty acid production only in Prevotella-abundant individuals, roughly forty percent of people lack the Gordonibacter species needed to convert ellagitannins into urolithins, and dysbiotic guts shunt tryptophan toward proinflammatory kynurenines instead of protective indoles. Nrf2’s dual role poses a clinical dilemma, since sustained activation could promote tumor progression in patients with premalignant lesions, and timing matters, as Nrf2 activation works best before injury onset. There are no standardized clinical biomarkers for hepatic Nrf2 activity, animal models translate poorly, and regulatory frameworks for live biotherapeutic products are still maturing. The authors also caution that the relationship is a bidirectional closed loop, with Nrf2 activation reshaping bile acid profiles that in turn select for Nrf2-activating bacteria, a self-regulating circuit that remains largely a conceptual model. Even so, the framework offers something the field has lacked: a mechanistic explanation for why plant-rich diets, probiotics, and microbial metabolites protect the liver, and a roadmap for engineering that protection deliberately rather than leaving it to chance.

Subject of Research: Microbial regulation of the Nrf2 antioxidant signaling pathway in oxidative liver injury via the gut-liver axis

Article Title: Targeting Nrf2 in oxidative liver injury: Expanding the role of gut microbiota and metabolites

Article References: Luo, Y., Jiang, Y., & Zhou, T. (2026). Targeting Nrf2 in oxidative liver injury: Expanding the role of gut microbiota and metabolites. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.09.006

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.09.006

Keywords: Nrf2, Keap1, gut-liver axis, gut microbiota, oxidative stress, liver injury, short-chain fatty acids, tryptophan metabolites, urolithins, ferroptosis, alcoholic liver disease, drug-induced liver injury

The clinical problem the team set out to address is far from niche. In patients receiving injected doxorubicin, hepatotoxicity has been documented repeatedly, with elevated liver enzymes, structural tissue damage, and in severe cases progressive fibrosis. Because doxorubicin remains a cornerstone of many treatment regimens, clinicians and researchers have long sought co-therapies that protect the liver without compromising the anticancer effect. Prior studies have tested an eclectic range of hepatoprotective agents, from creatine and hesperidin to naringin, salidroside, and metformin, each acting through partially overlapping but distinct molecular routes — antioxidant stress modulation, inflammasome suppression, or altered drug transport into hepatocytes. The new study adds bellidifolin to this growing arsenal and identifies a pathway that had not been prominently featured in the doxorubicin-liver story before: the Galectin-3/NLRP3 inflammatory axis.

The investigation began in silico. Using network pharmacology, a methodology that maps the relationships between a compound’s predicted molecular targets, disease-associated genes, and biological pathways, the researchers compiled a list of potential targets through which bellidifolin might counteract doxorubicin-induced liver injury. Out of the network analysis emerged a set of core targets dominated by players in the innate immune response: Caspase-1, NLRP3, IL-18, and IL-1β. Gene Ontology and KEGG pathway enrichment analyses converged on a single functional theme — the NLRP3 pathway, an inflammatory cascade whose dysregulation is increasingly implicated in drug-induced organ damage across the body.

To move beyond correlation and toward mechanism, the team turned to structural biology tools. Molecular docking positioned bellidifolin within the binding pockets of its predicted protein targets, and molecular dynamics simulation then tested whether the predicted interactions were stable over simulated time. The results pointed to two proteins in particular with which the small molecule showed strong binding affinity: Galectin-3, a beta-galactoside-binding lectin with well-known roles in fibrosis and inflammation, and NLRP3, the sensor protein that nucleates the inflammasome complex. This computational evidence gave the researchers a concrete hypothesis: bellidifolin might relieve liver injury by simultaneously engaging Galectin-3 and NLRP3, thereby dampening the downstream inflammatory program they drive.

The hypothesis then faced the wet laboratory. The researchers randomly divided mice into three groups: a control group, a group treated with doxorubicin, and a group receiving both doxorubicin and bellidifolin. When the animals were assessed, the protective effect of the natural compound was visible at every level of analysis examined. Hematoxylin and eosin staining revealed that bellidifolin attenuated the pathological changes doxorubicin inflicted on hepatic architecture, while Masson staining showed reduced collagen deposition, indicating less fibrosis. Biochemical assays of serum confirmed the histological picture: blood levels of alanine aminotransferase and aspartate aminotransferase, the two classic enzymatic signatures of liver damage, were significantly decreased in the bellidifolin-treated animals.

The most distinctive finding, however, concerned a form of cell death that has moved to the center of inflammatory disease research in the past decade: pyroptosis. Unlike apoptosis, the quiet, orderly death program that removes cells without stirring the immune system, pyroptosis is explosive. When the NLRP3 inflammasome assembles, it activates caspase-1, which cleaves the precursor forms of the inflammatory cytokines IL-1β and IL-18 into their mature, potent forms and also punches gasdermin pores in the cell membrane, causing the cell to swell and burst, spilling its contents into surrounding tissue. In the doxorubicin-treated mice, hepatocytes were undergoing pyroptosis, fueling a self-amplifying inflammatory loop. In the animals that also received bellidifolin, this pyroptotic process was substantially inhibited.

Western blot analysis and immunohistochemistry staining provided the molecular confirmation. Protein expression along the Gal-3/NLRP3 signaling pathway, elevated by doxorubicin, was suppressed by bellidifolin treatment, consistent with the docking predictions. The convergence of computational prediction and experimental measurement is what gives the study its strength: the same two proteins identified in silico as high-affinity partners of bellidifolin — Galectin-3 and NLRP3 — turned out to be the nodes through which the compound’s protective effect was expressed in living animals. The chain of evidence runs from network prediction, through molecular docking and dynamics, to histology, serum chemistry, and protein-level validation, forming an unusually complete arc for a single study.

The Galectin-3 connection is particularly intriguing in light of the broader literature. Galectin-3 has been shown in numerous contexts to sit upstream of NLRP3 inflammasome activation. Inhibiting Galectin-3 has been reported to limit microglial NLRP3/pyroptosis signaling in models of epilepsy and traumatic brain injury, to ameliorate epithelial pyroptosis in acute lung injury, and to reduce pro-fibrotic signaling in the liver. Galectin-3 is also overexpressed in advanced cirrhosis and has been studied as a marker of fibrosis and as a prognostic biomarker in hepatocellular carcinoma. The finding that bellidifolin binds both Galectin-3 and NLRP3 with strong affinity suggests it may be acting at a nodal point where fibrosis and inflammatory cell death intersect, which could have implications beyond chemotherapy-induced injury.

It is worth placing the new result alongside earlier work on bellidifolin itself, a xanthone-class compound from plants such as Gentianella acuta. Previous studies have found that bellidifolin inhibits proliferation of A549 lung cancer cells by regulating STAT3/COX-2 signaling, protects cardiac cells from hydrogen peroxide injury through the PI3K-Akt pathway, ameliorates isoprenaline-induced myocardial fibrosis via TGF-β1/Smads and p38 signaling, mitigates cardiac hypertrophy through the Nox4/ROS pathway, and eases nonalcoholic fatty liver disease-like changes induced by bisphenol F. Bellidifolin has also been shown to protect brain vascular pericytes from injury involving pyroptosis — a hint that its anti-pyroptotic activity, now demonstrated in the liver, may be a recurring theme in its pharmacology.

The study, approved by the Animal Ethics Committee of Hebei University of Chinese Medicine and supported by grants from Hebei provincial research programs, is a preclinical animal investigation, and the usual caveats apply. Dose optimization, pharmacokinetics, interactions with doxorubicin’s anticancer efficacy, and translation to human hepatotoxicity all remain open questions, and the authors note that no datasets were generated or analyzed beyond those reported. Still, by identifying a druggable inflammatory axis and demonstrating that a plant-derived small molecule engages it, the research offers a concrete starting point for developing hepatoprotective co-therapies that could one day let patients receive full doses of a life-saving chemotherapy drug without paying the price in liver damage. The Science of Nature (Sci Nat), Volume 113, article number 118, published the findings on 22 September 2026, adding a carefully validated page to the rapidly expanding catalogue of natural products capable of taming inflammatory cell death.

Subject of Research: Bellidifolin's protective mechanism against doxorubicin-induced liver injury through inhibition of Galectin-3/NLRP3-mediated pyroptosis

Article Title: Bellidifolin alleviates doxorubicin-induced hepatotoxicity: a study integrating network pharmacology, molecular docking, and experimental validation

Article References: Cao, Y., Chen, R., Zhang, W., Qin, Y., Liu, W., Li, A., Jia, Y., & Wu, J. (2026). Bellidifolin alleviates doxorubicin-induced hepatotoxicity: a study integrating network pharmacology, molecular docking, and experimental validation. The Science of Nature, 113(5), Article 118. https://doi.org/10.1007/s00114-026-02166-4

Image Credits: AI Generated

DOI: 10.1007/s00114-026-02166-4

Keywords: bellidifolin, doxorubicin, hepatotoxicity, liver injury, NLRP3 inflammasome, Galectin-3, pyroptosis, network pharmacology, molecular docking, molecular dynamics simulation, natural products, inflammation